Pulmonary Arterial Hypertension Market By Drug Class ( Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase 5 (PDE-5) Inhibitors & Soluble Guanylate Cyclase (sGC) Stimulators ), By Application ( Hospitals & Clinics ), Industry Trends, Estimation & Forecast, 2017-2025

Market Overview:

Pulmonary arterial hypertension, also called as (PAH) is a type of a broader condition known as pulmonary hypertension. In this rare condition, a high blood pressure is generated in the lung as a result of increased pressure in the vessels caused by hindrance in the small arteries, which are present the lung. The main cause of pulmonary arterial hypertension is usually unknown, but people encountering issues such as illegal drug use, liver disorders, blood clots in lungs, and congestive heart failure are found more prone to PAH. Moreover, factors such as increasing consumption of unhealthy and junk food, sedentary lifestyle, and growing number of cardiac patients are expected to stimulate the market growth. In addition to this, continuous favorable initiatives taken by government for spreading awareness regarding the treatment of pulmonary arterial hypertension, coupled with provision of funds for the research and development of PAH related drugs is expected to give a push to the market. However, being a rare condition, the relatively small presence of target population might act as a restraining factor for the market growth.
The report provides detailed qualitative and quantitative analysis of the pulmonary arterial hypertension Market. Market size and forecast in terms of value has been provided for the period – (2018 – 2025), for the segments namely drug class, and geography.

Pulmonary Arterial Hypertension Market Segmentation

By Drug Class
• Prostacyclin and Prostacyclin Analogs
• Endothelin Receptor Antagonists (ERAs)
• Phosphodiesterase 5 (PDE-5) Inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators

By Application
• Hospitals
• Clinics
• Others

By Geography

• North America
o U.S.
o Canada
o Mexico

• Europe
o UK
o Germany
o France
o Russia
o Rest of Europe

• Asia Pacific
o China
o Japan
o India
o Rest of APAC

• Rest of the world
o Latin America
o Middle East
o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources

CHAPTER 2. PULMONARY ARTERIAL HYPERTENSION MARKET OVERVIEW
2.1. PULMONARY ARTERIAL HYPERTENSION MARKET INTRODUCTION
2.2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET REVENUE AND GROWTH RATE, 2017-2025
2.2.1. Global Pulmonary Arterial Hypertension Market Revenue (Million USD) and Growth Rate (%), (2017-2025)

CHAPTER 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET BY DRUG CLASS, 2017-2025
3.1. PROSTACYCLIN AND PROSTACYCLIN ANALOGS
3.2. ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS)
3.3. PHOSPHODIESTERASE 5 (PDE-5) INHIBITORS
3.4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET REVENUE BY DRUG CLASS, 2017-2025
3.4.1. Global Pulmonary Arterial Hypertension Market Revenue (Million USD) and Share (%) By Drug Class, 2017-2025
3.4.2. Prostacyclin and Prostacyclin Analogs Market Revenue and Growth Rate, 2017-2025
3.4.3. Endothelin Receptor Antagonists (ERAs) Market Revenue and Growth Rate, 2017-2025
3.4.4. Phosphodiesterase 5 (PDE-5) Inhibitors Market Revenue and Growth Rate, 2017-2025

Note: Similar information coverage has been provided for other drug class sub-segment.

CHAPTER 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET BY APPLICATION, 2017-2025
4.1. HOSPITALS
4.2. CLINICS
4.3. OTHERS
4.4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET REVENUE BY APPLICATION, 2017-2025
4.4.1. Global Pulmonary Arterial Hypertension Market Revenue (Million USD) and Share (%) By Application, 2017-2025
4.4.2. Hospitals Market Revenue and Growth Rate, 2017-2025
4.4.3. Clinics Market Revenue and Growth Rate, 2017-2025
4.4.4. Others Market Revenue and Growth Rate, 2017-2025

CHAPTER 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. CANADA
5.1.3. MEXICO
5.2. EUROPE
5.2.1. UK
5.2.2. GERMANY
5.2.3. FRANCE
5.2.4. REST OF EUROPE
5.3. ASIA PACIFIC
5.3.1. CHINA
5.3.2. JAPAN
5.3.3. INDIA
5.3.4. REST OF APAC
5.4. REST OF THE WORLD
5.5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET REVENUE BY REGION, 2017-2025
5.5.1. Global Pulmonary Arterial Hypertension Market Revenue (Million USD) and Share (%) By Region, 2017-2025
5.5.2. North America Market Revenue and Growth Rate, 2017-2025
5.5.3. Europe Market Revenue and Growth Rate, 2017-2025
5.5.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
5.5.5. Rest of the world Market Revenue and Growth Rate, 2017-2025

CHAPTER 6. MARKET DETERMINANTS
6.1. MARKET DRIVERS
6.2. MARKET RESTRAINTS
6.3. MARKET OPPORTUNITIES
6.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET COMPETITION BY SERVICE PROVIDERS
7.1. GLOBAL PULMONARY ARTERIAL HYPERTENSION REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025)
7.1.1. Global Pulmonary Arterial Hypertension Revenue (Million USD) and Share (%) by Service Providers (2017-2025)
7.2. PULMONARY ARTERIAL HYPERTENSION MARKET COMPETITIVE SITUATION AND TRENDS
7.2.1. Pulmonary Arterial Hypertension Market Share (%) of Top 3 Service Providers
7.2.2. Pulmonary Arterial Hypertension Market Share (%) of Top 5 Service Providers

CHAPTER 8. COMPANY PROFILES
8.1. BAYER HEALTHCARE
8.1.1. Business Overview
8.1.2. Company Basic Information
8.1.3. Pulmonary Arterial Hypertension Product Details
8.1.4. Bayer HealthCare Pulmonary Arterial Hypertension Revenue
8.2. ACTELION PHARMACEUTICALS, LTD.
8.2.1. Business Overview
8.2.2. Company Basic Information
8.2.3. Pulmonary Arterial Hypertension Product Details
8.2.4. Actelion Pharmaceuticals, Ltd. Pulmonary Arterial Hypertension Revenue
8.3. NOVARTIS INTERNATIONAL AG
8.3.1. Business Overview
8.3.2. Company Basic Information
8.3.3. Pulmonary Arterial Hypertension Product Details
8.3.4. Novartis International AG Pulmonary Arterial Hypertension Revenue
8.4. GILEAD SCIENCES, INC.
8.4.1. Business Overview
8.4.2. Company Basic Information
8.4.3. Pulmonary Arterial Hypertension Product Details
8.4.4. Gilead Sciences, Inc. Pulmonary Arterial Hypertension Revenue
8.5. GLAXOSMITHKLINE PLC
8.5.1. Business Overview
8.5.2. Company Basic Information
8.5.3. Pulmonary Arterial Hypertension Product Details
8.5.4. GlaxoSmithKline plc Pulmonary Arterial Hypertension Revenue
8.6. UNITED THERAPEUTICS CORPORATION
8.6.1. Business Overview
8.6.2. Company Basic Information
8.6.3. Pulmonary Arterial Hypertension Product Details
8.6.4. United Therapeutics Corporation Pulmonary Arterial Hypertension Revenue
8.7. PFIZER, INC.
8.7.1. Business Overview
8.7.2. Company Basic Information
8.7.3. Pulmonary Arterial Hypertension Product Details
8.7.4. Pfizer, Inc. Pulmonary Arterial Hypertension Revenue

CHAPTER 9. PULMONARY ARTERIAL HYPERTENSION MARKET VALUE CHAIN ANALYSIS
9.1. PULMONARY ARTERIAL HYPERTENSION INDUSTRIAL CHAIN ANALYSIS
9.2. PULMONARY ARTERIAL HYPERTENSION KEY RAW MATERIALS ANALYSIS
9.2.1. Key Raw Materials
9.2.2. Price Trend of Key Raw Materials
9.2.3. Key Suppliers of Raw Materials
9.3. MARKETING CHANNEL
9.3.1. Direct Marketing
9.3.2. Indirect Marketing
9.3.3. Distributors/Traders
9.4. CONSUMER ANALYSIS
9.4.1. Consumer 1
9.4.2. Consumer 2
9.4.3. Consumer 3
9.4.4. Consumer 4

• Bayer HealthCare
• Actelion Pharmaceuticals, Ltd.
• Novartis International AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• United Therapeutics Corporation
• Pfizer, Inc.